.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing sepsis requires precise antibiotic dosing, yet standard protocols often lead to subtherapeutic or toxic levels. Consequently, clinicians increasingly rely on a Piperacillin TDM assay to optimize therapy. Traditional methods like HPLC are often slow and complex. However, recent research introduces a miniaturized lab-on-a-disk (LoaD) format that automates this process. This innovation allows for rapid measurement of free piperacillin concentrations directly from serum samples within minutes.
The system utilizes a specialized enzymatic assay based on the BlaP99 β-lactamase. This enzyme facilitates a competition between piperacillin and a substrate that releases fluorescent umbelliferone upon hydrolysis. Furthermore, the lab-on-a-disk setup handles all microfluidic manipulations using robust centrifugal techniques. Specifically, the device processes only a few microliters of serum to provide clinically meaningful data. Therefore, this technology bridges the gap between laboratory accuracy and bedside clinical needs.
In addition to its speed, the LoaD system offers significant automation for Therapeutic Drug Monitoring (TDM). Researchers compared the results from this microfluidic strategy against conventional well-plate methods and found high consistency. Notably, the system minimizes human error by automating reagent mixing and detection. Moreover, the rapid turnaround time helps physicians adjust dosages quickly. This approach potentially reduces the risks of antibiotic resistance and dose-related neurotoxicity in the ICU.
The development of this miniaturized assay represents a significant step toward personalized medicine. By providing real-time data, it empowers critical care teams to maintain drug levels within the optimal therapeutic window. Future applications may extend this technology to other β-lactam antibiotics, further enhancing antimicrobial stewardship.
TDM ensures that the free drug concentration remains above the Minimum Inhibitory Concentration (MIC) for efficacy while preventing toxic levels that cause neurological side effects.
Lab-on-a-disk technology automates complex laboratory processes on a small centrifugal device, enabling rapid bedside testing with minimal sample volume.
The automated system provides accurate piperacillin concentration measurements within just a few minutes using only a few microliters of blood serum.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
1. Verlaine O et al. Enzymatic assay in a lab-on-a-disk format to measure free piperacillin concentration in serum. Biomed Microdevices. 2026 Mar 17. doi: undefined. PMID: 41843204.
2. Hagel S et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med. 2022 Mar;48(3):311-321.
3. Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy. 2021;41:220-33.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a miniaturized lab-on-a-disk system for rapid, automated piperacillin TDM at the bedside, enhancing clinical decision-making....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
